{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:50:57Z","timestamp":1759333857090,"version":"build-2065373602"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although MDR-TB is recognized as a significant threat, systematic descriptions of its long-term (&amp;gt;30\u202fyears) global spatiotemporal evolution patterns are still limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study conducted a 46-year spatiotemporal analysis of global MDR-TB (1990\u20132035) to provide key evidence for evaluating and refining the WHO End TB Strategy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used Global Burden of Disease data to identify identified temporal inflection points in ASIR, ASDR, and DALYs using Joinpoint regression. Spatial clustering was quantified using Moran\u2019s I and Getis-Ord hotspot analysis. A Bayesian age-period-cohort model projected MDR-TB incidence from 2022 to 2035.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The male-to-female ratio was approximately 1.5:1. Incidence was highest at 30\u201360\u202fyears, deaths at 60+, DALYs peak at 45\u201360; children under 14\u202fyears of age significantly affected. ASIR rose from 0.97\/100\u202fk (1990) to 6.39\/100\u202fk (2000), then declined (APC: \u22123.15%) post-2005 to 5.62\/100\u202fk (2021); males exhibited a sharper increase (+2.39%) and slower decline (\u22120.71%). ASDR peaked at 2.12\/100\u202fk (2002; males 27% higher). DALYs peaked at 89.05\/100\u202fk (2003). Sub-Saharan Africa is hyperendemic (Moran\u2019s I\u202f=\u202f12.38, <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001; Somalia: 57.25\/100\u202fk), with high-high clusters in Africa\/Kyrgyzstan. Projections: Global ASIR declines modestly (\u22121.62% by 2035), but 480,000 cases expected due to population growth; female incidence drops 7.27% (2025+), male trends stable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MDR-TB has proven more challenging than anticipated, with persistent hotspots in sub-Saharan Africa and a disproportionate impact on males, the older adults, and children. Despite a marginal decline in ASIR to 5.46 per 100,000, the absolute number of cases is projected to rise to 480,000 by 2035 due to sustained population growth and aging. This will seriously hinder the WHO End TB Strategy. Addressing MDR-TB should prioritize key populations and regions, targeted resources, tailored interventions, sustained investment in diagnostics and treatment, and stronger government support for patient care.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1660984","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:30:08Z","timestamp":1759210208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46\u202fyears (1990\u20132035): implications for achieving global end TB goals"],"prefix":"10.3389","volume":"13","author":[{"given":"Yunbin","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhou","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.anpedi.2016.03.009","article-title":"Tuberculosis en el adolescente; reto y oportunidad de evitar el contagio a la comunidad [Adolescent tuberculosis; a challenge and opportunity to prevent community transmission]","volume":"86","author":"Margarit","year":"2017","journal-title":"Pediatr (Barc)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1513\/AnnalsATS.201904-281OC","article-title":"Lung function and respiratory symptoms after tuberculosis in an American Indian population. The strong heart study","volume":"17","author":"Powers","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e074134","DOI":"10.1136\/bmjopen-2023-074134","article-title":"Epidemiological features and temporal trends of HIV-negative tuberculosis burden from 1990 to 2019: a retrospective analysis based on the global burden of disease study 2019","volume":"13","author":"Chen","year":"2023","journal-title":"BMJ Open"},{"year":"2024","key":"ref4"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e1004155","DOI":"10.1371\/journal.pmed.1004155","article-title":"The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study","volume":"20","author":"Portnoy","year":"2023","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.20529\/IJME.2024.060","article-title":"The dire struggle: India's unfulfilled promise to eliminate tuberculosis","author":"Anirvan","year":"2024","journal-title":"Indian J Med Ethics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","article-title":"Global Preserving Effective TB Treatment Study Investigators. Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study","volume":"17","author":"Sharma","year":"2017","journal-title":"Lancet Infect Dis."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1408316","DOI":"10.3389\/fpubh.2024.1408316","article-title":"Tracking multidrug resistant tuberculosis: a 30-year analysis of global, regional, and national trends","volume":"12","author":"Song","year":"2024","journal-title":"Front Public Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12879-024-09079-5","article-title":"Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019","volume":"24","author":"Lv","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0171800","DOI":"10.1371\/journal.pone.0171800","article-title":"Spatial patterns of multidrug resistant tuberculosis and relationships to socio-economic, demographic and household factors in Northwest Ethiopia","volume":"12","author":"Alene","year":"2017","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1550199","DOI":"10.3389\/fpubh.2025.1550199","article-title":"Trends and forecast of drug-resistant tuberculosis: a global perspective from the GBD study 2021","volume":"13","author":"Guo","year":"2025","journal-title":"Front Public Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.tube.2014.08.012","article-title":"Gene mutations in Mycobacterium tuberculosis: multidrug-resistant TB as an emerging global public health crisis","volume":"95","author":"Mishra","year":"2025","journal-title":"Tuberculosis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2196\/medinform.9309","article-title":"Potential application of digitally linked tuberculosis diagnostics for real-time surveillance of drug-resistant tuberculosis transmission: validation and analysis of test results","volume":"6","author":"Ng","year":"2018","journal-title":"JMIR Med Inform"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","year":"2020","journal-title":"Lancet (London, England)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"volume-title":"World Population Prospects 2024: Comprehensive Dataset","year":"2024","key":"ref17"},{"volume-title":"Age Standardization of Rates: A New WHO Standard (GPE Discussion Paper Series No. 31)","year":"2001","key":"ref18"},{"volume-title":"Natural Earth Data: Free Vector and Raster Map Data","year":"2023","key":"ref19"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-024-10126-4","article-title":"Analysis of the epidemiological trends of tuberculosis in China from 2000 to 2021 based on the joinpoint regression model","volume":"24","author":"Li","year":"2024","journal-title":"BMC Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/eurpub\/ckac164","article-title":"Cardiovascular mortality trends in Switzerland 1995\u20132018","volume":"32","author":"Sorrentino","year":"2022","journal-title":"Eur J Pub Health"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"602","DOI":"10.19428\/j.cnki.sjpm.2024.23547","article-title":"Analysis of the trend of mortality among residents of Fuling District, Chongqing from 2017 to 2022","volume":"36","author":"Xiaoming","year":"2024","journal-title":"Shanghai J Prev Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1186\/s12889-023-16930-y","article-title":"Mapping the stability of febrile illness hotspots in Punjab from 2012 to 2019-a spatial clustering and regression analysis","volume":"23","author":"Verma","year":"2023","journal-title":"BMC Public Health"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"012052","DOI":"10.1088\/1757-899X\/335\/1\/012052","article-title":"A comparison of weights matrices on computation of dengue spatial autocorrelation","volume":"335","author":"Suryowati","year":"2018","journal-title":"IOP Conference Series: Materials Sci Eng"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40201-020-00565-x","article-title":"Spatiotemporal analysis and hotspots detection of COVID-19 using geographic information system (March and April, 2020)","volume":"18","author":"Shariati","year":"2020","journal-title":"J Environ Health Sci Eng."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1186\/s12879-019-4705-9","article-title":"Epidemiological study of scarlet fever in Shenyang, China","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1007\/s13524-019-00801-6","article-title":"Bounding Analyses of Age-Period-Cohort Effects","volume":"56","author":"Fosse","year":"2019","journal-title":"Demography."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.35566\/jbds\/v2n2\/p3","article-title":"The performances of gelman-rubin and geweke's convergence diagnostics of Monte Carlo Markov chains in bayesian analysis","volume":"2","author":"Du","year":"2022","journal-title":"J Behav Data Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1586\/14787210.2014.870884","article-title":"The early bactericidal activity of antituberculosis drugs","volume":"12","author":"Diacon","year":"2014","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e00180","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.arbr.2017.07.005","article-title":"Diagnosis and treatment of drug-resistant tuberculosis","volume":"53","author":"Caminero","year":"2017","journal-title":"Archivos de Bronconeumolog\u00eda (English Edition)"},{"volume-title":"WHO consolidated guidelines on tuberculosis: module 3: diagnosis","year":"2020","key":"ref34"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/ph14050461","article-title":"Chemical classes presenting novel antituberculosis agents currently in different phases of drug development: A 2010\u20132020 review","volume":"14","author":"Angula","year":"2021","journal-title":"Pharmaceuticals"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e220","DOI":"10.52225\/narra.v3i2.220","article-title":"Risk factors of MDR-TB and impacts of COVID-19 pandemic on escalating of MDR-TB incidence in lower-middle-income countries: A scoping review","volume":"3","author":"Ichsan","year":"2023","journal-title":"Narra J"},{"volume-title":"Global tuberculosis report 2023","year":"2023","key":"ref38"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1700216","DOI":"10.1183\/13993003.00216-2017","article-title":"Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease","volume":"50","author":"Imtiaz","year":"2017","journal-title":"Eur Respir J"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e0271511","DOI":"10.1371\/journal.pone.0271511","article-title":"Prevalence of modifiable risk factors of tuberculosis and their population attributable fraction in Iran: a crosssectional study","volume":"17","author":"Sadeghi","year":"2022","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1016\/S2468-2667(21)00033-5","article-title":"Community-based active case-finding interventions for tuberculosis: a systematic review","volume":"6","author":"Burke","year":"2021","journal-title":"Lancet Public Health"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.18203\/2394-6040.ijcmph20172828","article-title":"Risk factors of multi-drug resistant tuberculosis in urban Allahabad, India","volume":"4","author":"Raazi","year":"2017","journal-title":"Int J Commun Med Public Health"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1156249","DOI":"10.3389\/fphar.2023.1156249","article-title":"Global trends in the incidence rates of MDR and XDR tuberculosis: findings from the global burden of disease study 2019","volume":"14","author":"Bu","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3904\/kjim.2024.029","article-title":"Timing and predictors of death during treatment in patients with multidrug\/rifampin-resistant tuberculosis in South Korea","volume":"39","author":"Son","year":"2024","journal-title":"Korean J Intern Med"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5588\/ijtld.17.0357","article-title":"The burden of multidrug-resistant tuberculosis in children","volume":"22","author":"Jenkins","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1183\/13993003.00637-2016","article-title":"First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline","volume":"48","author":"Tadolini","year":"2016","journal-title":"Eur Respir J"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s13063-018-3070-0","article-title":"Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)","volume":"19","author":"Seddon","year":"2018","journal-title":"Trials"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.ijid.2021.02.107","article-title":"Global tuberculosis report 2020\u2013reflections on the global TB burden, treatment and prevention efforts","volume":"113","author":"Chakaya","year":"2021","journal-title":"Int J Infect Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3018(23)00111-X","article-title":"Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis","volume":"10","author":"Stannah","year":"2023","journal-title":"Lancet HIV"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"781","DOI":"10.4102\/ajlm.v7i2.781","article-title":"Drug resistant tuberculosis in Africa: Current status, gaps and opportunities","volume":"7","author":"Ismail","year":"2018","journal-title":"Afr J Lab Med."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1186\/s12889-015-2117-3","article-title":"Completeness and reliability of the Republic of South Africa National Tuberculosis (TB) surveillance system","volume":"15","author":"Podewils","year":"2015","journal-title":"BMC Public Health"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"16624","DOI":"10.1038\/s41598-021-95967-8","article-title":"Long-term trends of tuberculosis incidence and mortality in four central African countries","volume":"11","author":"Martial","year":"2021","journal-title":"Sci Rep"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/23288604.2018.1441621","article-title":"Responding to health system failure on tuberculosis in southern Africa","volume":"4","author":"Hartel","year":"2018","journal-title":"Health Syst Reform"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e13901","DOI":"10.1371\/journal.pone.0013901","article-title":"Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa","volume":"5","author":"Cox","year":"2010","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/8110229","article-title":"Rapid growth of the world population and its socioeconomic results","volume":"2022","author":"Sadigov","year":"2022","journal-title":"ScientificWorldJournal"},{"article-title":"Fiscal challenges and inclusive growth in ageing societies, OECD Economic Policy Papers, No. 27, OECD Publishing, Paris","year":"2019","author":"Rouzet","key":"ref56"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"18099","DOI":"10.1038\/s41598-019-54561-9","article-title":"Projecting the impact of variable MDR-TB transmission efficiency on long-term epidemic trends in South Africa and Vietnam","volume":"9","author":"Salvatore","year":"2019","journal-title":"Sci Rep"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"S2213-2600(17)30079-6","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"15","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e2021022","DOI":"10.4178\/epih.e2021022","article-title":"Controlling the drug-resistant tuberculosis epidemic in India: challenges and implications","volume":"43","author":"Husain","year":"2021","journal-title":"Epidemiol Health"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12941-025-00786-8","article-title":"Drug-resistant tuberculosis profiles among patients presenting at the antituberculosis center of Brazzaville, republic of Congo","volume":"24","author":"Ngouama","year":"2025","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e0321553","DOI":"10.1371\/journal.pone.0321553","article-title":"Spatial analysis of drug resistant tuberculosis (DRTB) incidence and relationships with determinants in Rio de Janeiro state, 2010 to 2022","volume":"20","author":"Pungartnik","year":"2025","journal-title":"PLoS One"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1660984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:30:10Z","timestamp":1759210210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1660984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":61,"alternative-id":["10.3389\/fpubh.2025.1660984"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1660984","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"1660984"}}